Neusignal Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series B

  • Investors
  • 15

Neusignal Therapeutics General Information

Description

Developer of small molecule drugs intended to cure brain diseases and overcome central nervous system diseases. The company engages in the research and development of therapeutic agents for dementia and psychiatric disorders and overcoming central nervous system diseases, enabling patients with brain diseases to solve their various problems related to brain health.

Contact Information

Website
www.neusignal-tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3-11-5 Nihonbashi Honcho
  • Nihonbashi Life Science Building 2, Room 604
  • Chuo-ku
  • Japan
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 3-11-5 Nihonbashi Honcho
  • Nihonbashi Life Science Building 2, Room 604
  • Chuo-ku
  • Japan

Neusignal Therapeutics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neusignal Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 30-Jun-2026 Completed Generating Revenue
4. Grant 31-Jan-2025 Completed Generating Revenue
3. Early Stage VC (Series A) 31-Jan-2025 Completed Generating Revenue
2. Seed Round 01-Mar-2024 $8.89M $8.89M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Neusignal Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neusignal Therapeutics Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Neusignal Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018310024-A1 Adamantylmethylamine derivative and use thereof as pharmaceutical Active 02-Aug-2017
AU-2018310024-B2 Adamantylmethylamine derivative and use thereof as pharmaceutical Active 02-Aug-2017
CA-3071615-A1 Adamantylmethylamine derivative and use thereof as pharmaceutical Active 02-Aug-2017
CA-3071615-C Adamantylmethylamine derivative and use thereof as pharmaceutical Active 02-Aug-2017
EP-3663279-A1 Adamantylmethylamine derivative and use thereof as pharmaceutical Pending 02-Aug-2017 C07C233/13
To view Neusignal Therapeutics’s complete patent history, request access »

Neusignal Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neusignal Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel Bridge Angel Group Minority
DCI Partners Venture Capital Minority
Gogin Capital PE/Buyout Minority
Nissay Capital Venture Capital Minority
Red Capital (Japan) Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

Neusignal Therapeutics FAQs

  • When was Neusignal Therapeutics founded?

    Neusignal Therapeutics was founded in 2022.

  • Where is Neusignal Therapeutics headquartered?

    Neusignal Therapeutics is headquartered in Chuo-ku, Japan.

  • What is the size of Neusignal Therapeutics?

    Neusignal Therapeutics has 20 total employees.

  • What industry is Neusignal Therapeutics in?

    Neusignal Therapeutics’s primary industry is Drug Discovery.

  • Is Neusignal Therapeutics a private or public company?

    Neusignal Therapeutics is a Private company.

  • What is Neusignal Therapeutics’s current revenue?

    The current revenue for Neusignal Therapeutics is .

  • How much funding has Neusignal Therapeutics raised over time?

    Neusignal Therapeutics has raised $16.2M.

  • Who are Neusignal Therapeutics’s investors?

    Angel Bridge, DCI Partners, Gogin Capital, Nissay Capital, and Red Capital (Japan) are 5 of 15 investors who have invested in Neusignal Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process